普卡那肽（Trulance）用于治疗慢性特发性便秘和便秘型肠易激综合征。
Plecanatide (Trulance) for Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation.
作者信息
Kamuda Julia A, Mazzola Nissa
出版信息
P T. 2018 Apr;43(4):207-232.
Abstract
Plecanatide (Trulance) for chronic idiopathic constipation and irritable bowel syndrome with constipation.
摘要
普卡那肽（Trulance）用于治疗慢性特发性便秘和便秘型肠易激综合征。
相似文献
1
2
Plecanatide for Treatment of Chronic Constipation and Irritable Bowel Syndrome.普卡必利治疗慢性便秘和肠易激综合征。
Am J Med. 2019 May;132(5):572-575. doi: 10.1016/j.amjmed.2018.11.027. Epub 2018 Dec 11.
3
Plecanatide: First Global Approval.普卡那肽：全球首次批准。
Drugs. 2017 Apr;77(5):593-598. doi: 10.1007/s40265-017-0718-0.
4
Efficacy and Tolerability of Guanylate Cyclase-C Agonists for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis.鸟苷酸环化酶 C 激动剂治疗便秘型肠易激综合征和慢性特发性便秘的疗效和耐受性：系统评价和荟萃分析。
Am J Gastroenterol. 2018 Mar;113(3):329-338. doi: 10.1038/ajg.2017.495. Epub 2018 Jan 30.
5
Efficacy and safety of plecanatide in treating constipation predominant irritable bowel syndrome.普卡那肽治疗便秘型肠易激综合征的疗效与安全性。
Expert Opin Pharmacother. 2018 Feb;19(2):177-183. doi: 10.1080/14656566.2018.1427733. Epub 2018 Jan 29.
6
Plecanatide for the treatment of constipation-predominant irritable bowel syndrome.普卡必利治疗便秘型肠易激综合征。
Expert Rev Gastroenterol Hepatol. 2020 Feb;14(2):71-84. doi: 10.1080/17474124.2020.1722101. Epub 2020 Feb 5.
7
Plecanatide (Trulance) for chronic idiopathic constipation.
Med Lett Drugs Ther. 2017 Apr 24;59(1519):66-68.
8
Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials.普卡必利治疗便秘型肠易激综合征的疗效、安全性和耐受性：两项 3 期随机临床试验结果。
Am J Gastroenterol. 2018 May;113(5):735-745. doi: 10.1038/s41395-018-0026-7. Epub 2018 Mar 15.
9
Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.便秘型肠易激综合征和慢性特发性便秘的现有及新出现的治疗方法：聚焦于促分泌剂。
Pharmacotherapy. 2015 Jun;35(6):613-30. doi: 10.1002/phar.1594. Epub 2015 May 27.
10
Long-term treatment with plecanatide was safe and tolerable in patients with irritable bowel syndrome with constipation.普卡必利治疗便秘型肠易激综合征患者的长期安全性和耐受性良好。
Curr Med Res Opin. 2019 Jan;35(1):81-85. doi: 10.1080/03007995.2018.1527303. Epub 2018 Oct 9.
引用本文的文献
1
Patient-Centered Approach in IBS-C Management.肠易激综合征便秘型管理中的以患者为中心的方法
Gastroenterol Hepatol (N Y). 2025 Jun;21(6):362-373.
2
Raising Expectations in IBS-C Management.提高IBS-C管理的期望。
Gastroenterol Hepatol (N Y). 2025 Apr;21(4):218-231.
3
A Case Study in the IBS-C Management Continuum: Assessing Patient Response and Tailoring Treatment.肠易激综合征便秘型管理连续统一体的案例研究：评估患者反应并调整治疗方案
Gastroenterol Hepatol (N Y). 2024 Jul;20(7):383-427.
4
Enteroendocrine cell regulation of the gut-brain axis.肠道内分泌细胞对肠-脑轴的调节。
Front Neurosci. 2023 Nov 7;17:1272955. doi: 10.3389/fnins.2023.1272955. eCollection 2023.
5
Abdominal Pain in Inflammatory Bowel Disease: An Evidence-Based, Multidisciplinary Review.炎症性肠病中的腹痛：一项基于证据的多学科综述
Crohns Colitis 360. 2023 Sep 26;5(4):otad055. doi: 10.1093/crocol/otad055. eCollection 2023 Oct.
6
Understanding the Current Approaches in the Management of IBS-C: A Case Study.理解肠易激综合征便秘型（IBS-C）的当前管理方法：一项案例研究
Gastroenterol Hepatol (N Y). 2023 Jun;19(6):328-335.
7
Advancement from Small Peptide Pharmaceuticals to Orally Active Piperazine-2,5-dion-Based Cyclopeptides.从小肽药物到具有口服活性的哌嗪-2,5-二酮为基础的环肽的进展。
Int J Mol Sci. 2023 Aug 31;24(17):13534. doi: 10.3390/ijms241713534.
8
Abnormal Uroguanylin Immunoreactive Cells Density in the Duodenum of Patients with Diarrhea-Predominant Irritable Bowel Syndrome Changes following Fecal Microbiota Transplantation.腹泻型肠易激综合征患者十二指肠中尿鸟苷素免疫反应性细胞密度异常在粪便微生物群移植后的变化
Gastroenterol Res Pract. 2020 Feb 4;2020:3520686. doi: 10.1155/2020/3520686. eCollection 2020.
9
Pharmacokinetics of Toxin-Derived Peptide Drugs.毒素衍生肽类药物的药代动力学。
Toxins (Basel). 2018 Nov 20;10(11):483. doi: 10.3390/toxins10110483.
本文引用的文献
1
American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation.美国胃肠病学会关于肠易激综合征和慢性特发性便秘管理的专著。
Am J Gastroenterol. 2014 Aug;109 Suppl 1:S2-26; quiz S27. doi: 10.1038/ajg.2014.187.
2
Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis.社区中慢性特发性便秘的患病率及相关危险因素：系统评价和荟萃分析。
Am J Gastroenterol. 2011 Sep;106(9):1582-91; quiz 1581, 1592. doi: 10.1038/ajg.2011.164. Epub 2011 May 24.
3
Association between physical activity, fiber intake, and other lifestyle variables and constipation in a study of women.一项针对女性的研究中，身体活动、纤维摄入量及其他生活方式变量与便秘之间的关联。
Am J Gastroenterol. 2003 Aug;98(8):1790-6. doi: 10.1111/j.1572-0241.2003.07591.x.
4
Effect of increased fluid intake on stool output in normal healthy volunteers.增加液体摄入量对正常健康志愿者粪便排出量的影响。
J Clin Gastroenterol. 1999 Jan;28(1):29-32. doi: 10.1097/00004836-199901000-00006.
5
The treatment of chronic constipation in adults. A systematic review.成人慢性便秘的治疗。一项系统评价。
J Gen Intern Med. 1997 Jan;12(1):15-24. doi: 10.1046/j.1525-1497.1997.12103.x.
Zotero 插件